A robust evaluation of 49 high‐dose‐rate prostate brachytherapy treatment plans including all major uncertainties
Journal of Applied Clinical Medical Physics · 2024
DOI: 10.1002/acm2.14182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Clinical Medical Physics, 2024. Verfasst von Andrew Christopher Kennedy und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Physical Sciences, University of Adelaide, Adelaide, SA, Australia. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Uncertainties in radiotherapy cause deviation from the planned dose distribution and may result in delivering a treatment that fails to meet clinical objectives. The impact of uncertainties is unique to the patient anatomy and the needle locations in HDR prostate brachytherapy. Evaluating this impact during treatment planning is not common practice, relying on margins around the target or organs‐at‐risk to account for uncertainties.
Purpose
A robust evaluation framework for HDR prostate brachytherapy treatment plans was evaluated on 49 patient plans, measuring the range of possible dosimetric outcomes to the patient due to 14 major uncertainties.
Methods
Patient plans were evaluated for their robustness to uncertainties by simulating probable uncertainty scenarios. Five‐thousand probabilistic and 1943 worst‐case scenarios per patient were simulated by changing the position and size of structures and length of dwell times from their nominal values. For each uncertainty scenario, the prostate D 90 and maximum doses to the urethra, D 0.01cc , and rectum, D 0.1cc , were calculated.
Results
The D 90 was an average 1.16 ± 0.51% (mean ± SD) below nominal values for the probabilistic scenarios; the D 0.01cc metric was 2.24 ± 0.90% higher; and D 0.1cc was greater by 0.48 ± 0.30%. The D 0.01cc and D 90 metrics were more sensitive to uncertainties than D 0.1cc , with a median of 79.0% and 84.9% of probabilistic scenarios passing the constraints, compared to 96.5%. The median pass‐rate for scenarios that passed all three metrics simultaneously was 63.4%.
Conclusions
Assessing treatment plan robustness improves plan quality assurance, is achievable in less than 1‐min, and identifies treatment plans with poor robustness, allowing re‐optimization before delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Physical Sciences, University of Adelaide, Adelaide, SA, Australia.
- Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia.
- Australian Bragg Centre for Proton Therapy and Research, Adelaide, SA, Australia.
ORCID-Profile: Andrew Christopher Kennedy
Zitieren
APA
Kennedy, A. C., Douglass, M. J. J., & Santos, A. M. C. (2024). A robust evaluation of 49 high‐dose‐rate prostate brachytherapy treatment plans including all major uncertainties. Journal of Applied Clinical Medical Physics. https://doi.org/10.1002/acm2.14182
Vancouver
Kennedy AC, Douglass MJJ, Santos AMC. A robust evaluation of 49 high‐dose‐rate prostate brachytherapy treatment plans including all major uncertainties. Journal of Applied Clinical Medical Physics. 2024. doi:10.1002/acm2.14182
BibTeX
@article{Kennedy2024,
author = {Kennedy, Andrew Christopher and Douglass, Michael John James and Santos, Alexandre Manuel Caraça},
title = {A robust evaluation of 49 high‐dose‐rate prostate brachytherapy treatment plans including all major uncertainties},
journal = {Journal of Applied Clinical Medical Physics},
year = {2024},
doi = {10.1002/acm2.14182}
}
EUVIMED